Evidence map›Paper›PMID 39043871›Full record

Trial reportScientific reports2024

Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.

Michele Clerico, Simone Ferrero, Beatrice Alessandria, Gian Maria Zaccaria, Elisa Genuardi, Simone Ragaini, Rita Tavarozzi, Federica Cavallo, Stefan Hohaus, Gerardo Musuraca and 16 more

Registry-linked trialAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02354313 (A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02354313 phase3unknown statusnot on this map

A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma

TypeinterventionalSponsorFondazione Italiana Linfomi - ETSRan2010 to 2019Enrolled300ConditionsMANTLE CELL LYMPHOMAArmsLenalidomide
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Michele ClericoDivision of Hematology, AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
Simone FerreroDivision of Hematology, AOU "Città della Salute e della Scienza di Torino", Torino, Italy. simone.ferrero@unito.it.
Beatrice AlessandriaDepartment of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
Gian Maria ZaccariaDepartment of Electrical and Information Engineering (DEI), Polytechnic University of Bari, Bari, Italy.
Elisa GenuardiDepartment of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
Simone RagainiDivision of Hematology, AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
Rita TavarozziSC Ematologia Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Federica CavalloDivision of Hematology, AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
Stefan HohausInstitute of Hematology, Università Cattolica del Sacro Cuore and Fondazione Policlinico Univeristario A. Gemelli, Roma, Italy.
Gerardo MusuracaIRCCS, IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori", Meldola, Italy.
Angelo Michele CarellaDepartment of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
Caterina StelitanoDepartment of Hematology, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Monica TaniUOC di Ematologia, Ospedale S. Maria delle Croci, Ravenna, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Jacopo OlivieriClinica Ematologica, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Sara Veronica UsaiEmatologia e CTMO, Ospedale Businco, Cagliari, Italy.
Sara GalimbertiDivision of Hematology, University Hospital of Pisa, Pisa, Italy.
Francesca ReDivision of Immuno-Haematology, AOU Parma, Parma, Italy.
Michael MianInnovation, Research and Teaching Service (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Bolzano, Italy.
Claudia CastellinoDivision of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
Vincenzo PavoneOspedale Pia Fondazione Cardinale Panico, Tricase, Lecce, Italy.
Andrea EvangelistaUnit of Clinical Epidemiology, AOU "Città della Salute e della Scienza di Torino" and CPO Piemonte, Torino, Italy.
Benedetto BrunoDivision of Hematology, AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
Sergio CortelazzoOncology Unit, Humanitas/Gavazzeni Clinic, Bergamo, Italy.
Roberto PasseraDepartment of Medical Sciences, University of Torino, Torino, Italy.
Marco LadettoSC Ematologia Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the frontline high-dose phase 3 FIL-MCL0208 trial (NCT02354313), 8% of enrolled mantle cell lymphoma (MCL) patients could not be randomised to receive lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation (ASCT) due to inadequate hematological recovery and 52% of those who started LEN, needed a dose reduction due to toxicity. We therefore focused on the role played by CD34 + hematopoietic stem cells (PBSC) harvesting and reinfusion on toxicity and outcome. Overall, 90% (n = 245) of enrolled patients who underwent the first leukapheresis collected ≥ 4 × 10

Indexed as

Hematopoietic Stem Cell MobilizationLeukapheresisLymphoma, Mantle-CellTransplantation, AutologousAdultAgedAntigens, CD34FemaleHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansItalyLenalidomideMaleMiddle AgedAntigens, CD34LenalidomideAutologous stem cell transplantation (ASCT)Hematological recoveryLeukapheresis (LK)Mantle cell lymphoma (MCL)Peripheral blood stem cells (PBSC)

Identifiers

PMID39043871
PMCPMC11266400

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.